Research

Hormonal

In real-world clinical practice, tirzepatide produces significantly greater weight loss and higher rates of achieving 5%, 10%, and 15% weight reduction thresholds compared to semaglutide in adults with overweight or obesity.

If you are choosing between semaglutide and tirzepatide for weight loss, real-world data suggests tirzepatide is likely to produce roughly double the weight loss at one year compared to semaglutide. You are also significantly more likely to hit major weight loss milestones (5%, 10%, 15%) with tirzepatide. However, this comes with the caveat that these specific findings are based on formulations labeled for Type 2 Diabetes, and insurance coverage may be more difficult to obtain for tirzepatide than semaglutide.

GoodSupportsHIGH confidence
In this large, propensity-matched, real-world analysis, individuals with overweight or obesity treated with tirzepatide were significantly more likely to achieve clinically meaningful weight loss and larger reductions in body weight compared to those treated with semaglutide.
Patricia J. Rodriguez et al. · JAMA Internal Medicine · 2024

Why this rating

Large sample size (n=41,223), rigorous propensity score matching, and real-world applicability, though it is an observational study (preprint) rather than a head-to-head RCT.

Source

Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity

Patricia J. Rodriguez et al. · JAMA Internal Medicine · 2024

DOI 10.1001/jamainternmed.2024.2525

preprint · n=41223Cited 261×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →